Renaissance Technologies
NRSN icon

Renaissance Technologies’s NeuroSense Therapeutics NRSN Stock Holding History

Renaissance Technologies’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-71,100
Closed -$129K – 3819
2024
Q1 		$129K Buy
+71,100
New +$95.7K ﹤0.01% 3322
2023
Q1 		– Sell
-18,433
Closed -$22K – 4266
2022
Q4 		$22K Sell
18,433
-35,867
-66% -$57K ﹤0.01% 3946
2022
Q3 		$97K Buy
+54,300
New +$111K ﹤0.01% 3606

Other funds holding NRSN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Renaissance Technologies's NRSN Position: Q2 2024 in Review

Renaissance Technologies sold out of NeuroSense Therapeutics (NRSN) in Q2 2024, closing a stake of 71,100 shares — an estimated $129K sold.

Renaissance Technologies first reported a position in NRSN in Q3 2022 and held it in 3 quarters. The position peaked at $129K in Q1 2024. 7 funds tracked by Wall St. Rank hold NRSN as of Q2 2024.

  • Renaissance Technologies reported no remaining NeuroSense Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Renaissance Technologies sold 71,100 NeuroSense Therapeutics shares in Q2 2024, an estimated $129K.
  • Renaissance Technologies first reported a position in NeuroSense Therapeutics in Q3 2022 and held it in 3 quarters.
  • Renaissance Technologies's NeuroSense Therapeutics position peaked at $129K in Q1 2024.
  • 7 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.